GENE ONLINE|News &
Opinion
Blog

2020-09-22| Special

Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies

by GeneOnline
Share To
Among the 100 or so phytocannabinoids that have been identified in the Cannabis sativa herb, delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been explored the most for pharmacological use. Although 33 states have approved the use of cannabis in the U.S. for medicinal purposes, the U.S. Drug Enforcement Administration recognizes it as a Schedule I drug.

This has impeded the use of cannabis in clinical research, potentially obscuring physicians and nurses about its safety, efficacy, and dosage for pharmaceutical applications through rigorous double-blinded, placebo-controlled studies. Besides, cannabinoid-containing substances obtained for research purposes are not chemically or physically representative of the legal cannabis market.

GO Prime with only $1.49 now

LATEST
GSK Bets $593 Million To License Scynexis’ Oral Antifungal
2023-03-31
3D Printed Brain Model Could Aid in Neurosurgery
2023-03-31
Latest Study on Neuronal Gene Expression May Shed Light on the Memory Formation Process
2023-03-30
Emergent BioSolutions’ Over-The-Counter Naloxone Nasal Spray Receives FDA Greenlight
2023-03-30
Current Trends of iPSC Manufacturing and Clinical Applications – An Interview with Professor Xianmin Zeng
2023-03-29
U.S.-German Joint Discovery May Spark Breakthrough in Diabetes Research
2023-03-29
Merck Regains Worldwide Rights to BAVENCIO After Parting Ways with Pfizer
2023-03-29
Scroll to Top